	US 12,331,085 B2
	Methods and compositions related to the next generation vaccine
Wendy L. Picking, Lawrence, KS (US); and William D. Picking, Lawrence, KS (US)
Assigned to University of Kansas, Lawrence, KY (US)
Filed by UNIVERSITY OF KANSAS, Lawrence, KS (US)
Filed on Sep. 12, 2022, as Appl. No. 17/931,356.
Application 17/931,356 is a continuation of application No. 17/053,544, granted, now 11,439,700, previously published as PCT/US2019/030694, filed on May 3, 2019.
Claims priority of provisional application 62/667,599, filed on May 6, 2018.
Prior Publication US 2023/0112697 A1, Apr. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/104 (2006.01); A61K 39/02 (2006.01); C07K 14/21 (2006.01); C07K 14/235 (2006.01); C07K 14/245 (2006.01); C07K 14/28 (2006.01)

CPC C07K 14/28 (2013.01) [A61K 39/104 (2013.01); A61K 39/107 (2013.01); C07K 14/21 (2013.01); C07K 14/235 (2013.01); C07K 14/245 (2013.01); C07K 2319/00 (2013.01)]

11 Claims

1. A fusion polypeptide comprising (i) a fusion of PcrV needle tip protein of Pseudomonas spp. and PopB translating protein of Pseudomonas spp., wherein the fusion comprises the amino acid sequence set forth in SEQ ID NO: 36; and ii) a double mutant labile toxin (dmLT) of Escherichia coli or an antigenic fragment thereof, or cholera toxin or an antigenic fragment thereof.